Manu Smriti Singh

Manu Smriti Singh

Associate Professor
manu.singh@mahindrauniversity.edu.in

Manu Smriti Singh works in the area of cancer nanomedicine, specifically drug and gene delivery. She is interested in understanding the role of non-cancer supporting cells of the tumor microenvironment and early tumorigenesis. This has implications in early cancer diagnosis and development of targeted nanomedicine.

2010-2014

  • Ph.D. (2010-2014); University of Bonn, Bonn, Germany

2006-2008

  • M.Sc. (2006-2008); Pondicherry University, Pondicherry, India

2002-2005

  • B.Sc. (2002-2005); University of Allahabad, Prayagraj, Uttar Pradesh, India

2023- Present

  • 2023- Present Associate Professor Center for Life Sciences Mahindra University

2023

  • Visiting Professor, Department of Biochemistry and Molecular Biology, Hadassah Medical School Hebrew University of Jerusalem: (2023)

2016

  • OncoRay – Center for Radiation Research in Oncology, Faculty of Medicine, Technische Universitaet- Dresden, Germany: (2016)

2015-2020

  • Centre of Nanotechnology & Nanoscience, Department of Cell Research and Immunology, Tel-Aviv University, Israel: (2015-2020)

2008

  • Product Development Cell-I, National Institute of Immunology: (2008)

2007

  • Transgenic and Gene Knockout Lab, Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India: (2007)

Publications

2023

  • Raina N; Shiekh PA; Kumar A; Singh MS; Gupta PK; Gupta M (2023). Oxygen-generating nanomaterials for chronic wound management. Nanomedicine. 18 (11)
  • Modi SK, Gaur S, Sengupta M, Singh MS*. (2023) Mechanistic insights into Nanoparticle Surface-Bacterial Membrane Interactions in overcoming Antibiotic Re

    • 2022

  • Swetha KL; Maravajjala KS; Li SD; Singh MS*; Roy A. (2022) Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation. Drug Delivery and Translational Research. 13, 105-134.
  • Rastogi A; Yadav K; Mishra A; Singh MS; Chaudhary S; Manohar R; Parmar AS. (2022). Early diagnosis of lung cancer using magnetic nanoparticles-integrated systems. Nanotechnology Reviews. 2022-0032.

    • 2021

  • Singh MS; Ramishetti S; Landesman-Milo D; Goldsmith M; Chatterjee S; Palakuri R; Peer D. (2021). Therapeutic Gene Silencing using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer. Small. 17(19);e2100287.
  • Thakur K; Singh MS; Feldstein-Davydova S; Hannes V; Hershkovitz D; Tsuriel T. (2021). Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer. Genes. 12(8); 1171.

    • 2020

  • Singh MS; Goldsmith M; Thakur K; Chatterjee S; Landesman-Milo D; Levy T; Kunz-Schughart LA; Barenholz Y; Peer D. (2020). An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. Nanoscale. 12;1894-1903.

    • 2017

  • Singh MS; Tammam S; Boushehri MAS; Lamprecht A. (2017). MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers. Pharm. Res. 126; 2-30.

    • 2016

  • Singh MS; Lamprecht A (2016). P-glycoprotein inhibition of drug resistant cell lines by nanoparticles. Drug Dev Ind Pharm. 42(2); 325-31.
  • Singh MS; Peer D (2016). siRNA delivery: Current trends and future perspectives. Ther. Deliv. 7(2); 51-53.

    • 2015

  • Singh MS; Lamprecht A (2015). Cargoing P-gp inhibitors via nanoparticle sensitize tumor cells against doxorubicin. Int J Pharm. 478, 745-752.
  • Singh MS; Juvale K; Wiese M; Lamprecht A (2015). Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation. Eur J Pharm Sci. 77:1-8.

    • 2014

  • Singh MS; Bhaskar S (2014). Nanoparticle immunotherapy in cancer management and research. Immunotargets Ther. 3; 121-134.

    • 2013

  • Roy A; Singh MS; Upadhyay P; Bhaskar S (2013). Nanoparticle mediated co-delivery of Paclitaxel and a TLR-4 agonist leads to better tumor regression and enhances anti-tumor immune response at the tumor microenvironment. Int J Pharm. 445; 171-80.

    • 2010

  • Roy A; Singh MS; Upadhyay P; Bhaskar S (2010). Combined chemo-immunotherapy as a prospective strategy to combat cancer: A nanoparticle based approach. Mol. Pharm. 7; 1778-1788.

    • Our lab focuses on developing nanomedicine based on understanding of the tumor microenvironment (TME), which majorly comprises of cancer cells but also sub-populations of non-cancerous supporting cells such as tumor endothelial cells, cancer-associated fibroblasts and immune cells. In vitro studies are preferentially performed on 3D cell culture over 2D monolayer culture for better clinical correlation with chemo/radioresistant patient’s tumor.

    3D Organoid or tumoroid cell culture have demonstrated to be an interface between in vitro and in vivo disease models and are thus advantageous for screening of drugs/nanomedicine. Long-term vision is to develop bionanomaterials for early diagnosis and therapeutics with the potential to be utilized in healthcare.

    Openings

    We work at the interface of nanomedicine development and microfluidics with focus on translational aspects. Along with conventional training, strong emphasis is put at collaborations, science communication, and industrial training. Following are encouraged to approach.

    JRFs from DST INSPIRE

    JRFs from ICMR / UGC / DBT / CSIR

    RAs with postdoc fellowships like NPDF, ICMR, DBT RA etc.

    For more details on our Science, please see our papers or write to manu.singh@mahindrauniversity.edu.in or mann2585@gmail.com

    You can also visit the lab by contacting us in advance.

    Funding
    POWER Grant (SERB, DST) in collaboration with IIT-BHU and BHU, Varanasi, India